Malaria drug | The Business Standard
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 29, 2022
SUNDAY, MAY 29, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা

Malaria drug

File Photo: The drug hydroxychloroquine is displayed by a pharmacist at a pharmacy in Provo, Utah, US, May 27, 2020. Reuters/George Frey/File Photo
Coronavirus chronicle

WHO halts hydroxychloroquine, HIV drugs in Covid trials after failure to reduce death

Hydroxychloroquine and a related compound chloroquine have been used for decades to treat malaria, as well as autoimmune disorders lupus and rheumatoid arthritis. Photo: AFP
Coronavirus chronicle

No benefit, higher death rate for malaria drug in coronavirus study

Trump told reporters at the daily White House briefing on the coronavirus outbreak that he had call Modi/Reuters
Coronavirus chronicle

Trump urges Modi to lift export hold on anti-malaria drug for Covid-19 treatment

Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017/ Reuters
Coronavirus chronicle

Malaria drug is biggest hope against coronavirus: Novartis CEO

Scientists are studying old drugs for possible use against the coronavirus. Photo: Collected
Coronavirus chronicle

Researchers find malaria drug potential for coronavirus treatment

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab